Entera Bio Ltd
ILILSEntera Bio Ltd (US:ENTX) — Biotechnology: Biological Products (No Diagnostic Substances). Liczba giełd, na których notowane są akcje spółki: 1. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.
O Firmie
- Strona
- enterabio.com
- Relacje Inwestorskie
- investors.enterabio.com/
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siedziba
- JERUSALEM, Israel
- Zarząd
- Miranda J. Toledano
- Najnowsze Raporty
- Pracownicy
- 20
- Akcje w Obrocie
- 173.14 mln na 2026-08-03
- Free Float
- 126.58 mln
- Kapitalizacja Rynkowa
- 507.6 mln USD
- Insiderzy
- 5.43%
- Inwestorzy Instytucjonalni
- 34.09%
- Branża (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- strata
- P/B
- 21.2
- FCF
- −11.0 mln USD
- Dług
- 3.89 mln USDujemny FCF — brak pokrycia
- Zyski i FCF — za 12 miesięcy do 30.06.2026 roku (najnowszy raport firmy).
- Zysk Netto
- NAV
Opis
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Giełdy i Tickery
| Giełda | Ticker | Waluta | Cena | Typ |
|---|---|---|---|---|
| US USA Stocks | ENTX | USD | 3.12 +0.65% | akcje zwykłe |
Wiadomości w Tym Tygodniu
Komunikaty prasowe ze strony firmy dla inwestorów, aktualizowane codziennie. Linki prowadzą na stronę firmy. Nagłówki są w oryginalnym języku, jak na stronie internetowej firmy.
Najwięksi Akcjonariusze
| Posiadacz | Udział | Akcje | Data Raportu |
|---|---|---|---|
| Knoll Capital Management… | 3.38% | 5.88 mln | 2026-06-30 |
| BVF Inc. | 1.39% | 2.43 mln | 2026-06-30 |
| TOLEDANO MIRANDA JAYNE (… | ≈0.49% | 847 135 | 2026-07-14 |
| Siren, L.L.C. | 0.42% | 736 457 | 2026-06-30 |
| Renaissance Technologies… | 0.21% | 368 847 | 2026-06-30 |
| LIEBERMAN GERALD M (Dire… | ≈0.21% | 363 254 | 2025-12-31 |
| Parkman Healthcare Partn… | 0.16% | 274 497 | 2026-06-30 |
| PNC Financial Services G… | 0.16% | 273 031 | 2026-06-30 |
| ELLIS SEAN (Director) | ≈0.12% | 208 132 | 2026-08-07 |
| Seven Fleet Capital Mana… | 0.11% | 191 354 | 2026-06-30 |
| BURSHTEIN GREGORY (Offic… | ≈0.11% | 189 033 | 2026-05-07 |
| Fidelity Concord Street… | 0.1% | 178 259 | 2026-08-31 |
| GALITZER HILLEL M.D. (Ch… | ≈0.09% | 163 566 | 2026-05-07 |
| TAITEL HAYA (Director) | ≈0.07% | 119 269 | 2026-08-07 |
| MALCA YONATAN (Director) | ≈0.06% | 100 231 | 2026-08-07 |
| OSTROV GERALD M (Directo… | ≈0.04% | 75 657 | 2025-12-31 |
| HighTower Advisors, LLC | 0.04% | 74 573 | 2026-06-30 |
| HRT Financial LP | 0.04% | 72 486 | 2026-06-30 |
| Schonfeld Strategic Advi… | 0.03% | 58 871 | 2026-06-30 |
| GERMANO GENO J (Director… | ≈0.02% | 40 000 | 2026-03-09 |
| YAACOV-GARBELI DANA CPA… | — | — | 2026-05-07 |
Zaloguj się przez Google